Tirzepatide: A Comprehensive Review of Its Metabolic Benefits for Weight Loss and Type 2 Diabetes

Over the past few years, tirzepatide has become one of the most discussed medications in the fields of obesity management and type 2 diabetes treatment. Its growing popularity is supported by large international clinical trials demonstrating remarkable weight loss, improved blood glucose control, favorable effects on lipid metabolism, and several additional metabolic benefits.

Unlike conventional GLP-1 receptor agonists, tirzepatide activates two incretin pathways simultaneously by targeting both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism of action provides broader metabolic effects than therapies acting on a single receptor.

In this review, we summarize current scientific evidence regarding the metabolic effects of tirzepatide, including its impact on:

• body weight reduction;
• appetite regulation and satiety;
• body composition;
• blood glucose and HbA1c;
• lipid profile;
• treatment safety and adverse effects.

Why Are Obesity and Type 2 Diabetes Growing Global Health Challenges?

Obesity and type 2 diabetes mellitus (T2DM) are among the most significant public health challenges worldwide. These conditions are closely linked and substantially increase the risk of cardiovascular disease, stroke, chronic kidney disease, neuropathy, retinopathy, and premature mortality.

Over recent decades, obesity prevalence has increased dramatically across nearly every region of the world, while the number of people living with type 2 diabetes continues to rise. Most individuals diagnosed with T2DM are also overweight or obese, creating a vicious cycle that makes disease management considerably more difficult.

For this reason, modern pharmacological research has focused on therapies capable of addressing several metabolic abnormalities simultaneously instead of targeting blood glucose alone.

What Is Tirzepatide?

Tirzepatide is a next-generation medication classified as a dual GLP-1/GIP receptor agonist. Because it stimulates two major incretin hormone pathways simultaneously, it is frequently referred to in scientific literature as a “twincretin”.

The drug is marketed under the brand name Mounjaro and has been approved for treating adults with type 2 diabetes. However, clinical studies have also demonstrated exceptional effectiveness for weight management, making it one of the most promising medications currently available for obesity treatment.

Tirzepatide is administered as a once-weekly subcutaneous injection. Depending on the clinical indication, doses range from 2.5 mg to 15 mg, with gradual dose escalation recommended to improve treatment tolerability.

Major Clinical Trials Evaluating Tirzepatide

The efficacy and safety of tirzepatide have been investigated in several large international randomized clinical trials. The two best-known research programs are SURMOUNT, focusing primarily on obesity management, and SURPASS, which evaluated the drug in patients with type 2 diabetes.

How Do GLP-1 and GIP Hormones Work?

After food is consumed, the intestine releases a group of hormones known as incretins. Among them, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) play central roles in regulating metabolism.

These hormones help the body respond efficiently to nutrient intake by stimulating insulin secretion, improving glucose utilization, and influencing appetite regulation within the central nervous system.

The primary physiological actions of GLP-1 include:

• stimulating glucose-dependent insulin secretion;
• reducing glucagon release;
• slowing gastric emptying;
• enhancing feelings of fullness;
• decreasing overall food intake.

Unlike traditional GLP-1 receptor agonists, tirzepatide simultaneously activates both GLP-1 and GIP receptors. This dual incretin mechanism is believed to explain its superior effects on weight reduction and glycemic control compared with therapies targeting only a single receptor.

How Were the Clinical Trials Conducted?

Most current knowledge regarding tirzepatide comes from two large international clinical development programs: SURMOUNT and SURPASS. Together, these randomized controlled trials enrolled thousands of participants from multiple countries, providing robust evidence regarding both efficacy and safety.

Although the two research programs evaluated the same medication, they focused on different patient populations:

• SURMOUNT primarily investigated obesity treatment and long-term weight management.
• SURPASS evaluated glycemic control and metabolic outcomes in adults with type 2 diabetes.

Across most studies, participants received weekly subcutaneous injections of tirzepatide at doses of 5 mg, 10 mg, or 15 mg over treatment periods ranging from 40 to 72 weeks. Clinical outcomes were compared with placebo, insulin therapy, semaglutide, or other standard diabetes treatments.

How Effective Is Tirzepatide for Weight Loss?

The impressive weight-loss results observed in clinical trials are largely responsible for tirzepatide’s rapid rise in popularity worldwide.

In the landmark SURMOUNT-1 trial, participants achieved average weight reductions after 72 weeks of treatment of:

• approximately 15% with the 5 mg dose;
• 19.5% with the 10 mg dose;
• 20.9% with the 15 mg dose.

By comparison, participants receiving placebo lost only about 3% of their initial body weight. Furthermore, more than 90% of patients receiving the highest tirzepatide dose achieved at least a 5% reduction in baseline body weight.

The SURMOUNT-2 study produced similarly encouraging findings in patients living with type 2 diabetes. Although weight reduction is generally more difficult in this population, tirzepatide still produced significantly greater weight loss than placebo.

Is Tirzepatide More Effective Than Semaglutide?

One of the most influential studies comparing modern obesity medications was the SURPASS-2 trial, which directly compared tirzepatide with semaglutide.

The results demonstrated that patients treated with tirzepatide consistently achieved greater reductions in body weight across nearly all dosage groups.

At the highest approved dose of 15 mg, average weight loss exceeded that achieved with semaglutide by approximately 5.5 kg. Tirzepatide also provided superior improvements in HbA1c and overall glycemic control.

Following publication of the SURPASS-2 trial, many experts began describing tirzepatide as one of the most effective pharmacological therapies currently available for obesity management.

Can Weight Loss Be Maintained After Treatment?

Long-term weight maintenance remains one of the greatest challenges in obesity treatment. The SURMOUNT-4 trial specifically evaluated whether patients could maintain previously achieved weight loss after initial treatment.

During the lead-in treatment phase, participants lost more than 20% of their body weight on average. They were then randomized to either continue tirzepatide therapy or switch to placebo.

One year later, investigators observed that:

• nearly 90% of patients who continued tirzepatide maintained most of their weight loss;
• patients switched to placebo gradually regained a significant portion of the lost weight.

These findings suggest that obesity should be considered a chronic condition requiring ongoing management rather than a short-term disease that can be permanently cured after a limited course of therapy.

How Does Tirzepatide Affect Body Composition?

Successful weight management involves more than simply reducing body weight. From a clinical perspective, preserving lean muscle mass while reducing body fat is considered the ideal outcome.

Evidence from several clinical trials suggests that tirzepatide promotes weight loss primarily through reductions in adipose tissue rather than indiscriminate loss of total body mass.

In the SURPASS-1 trial, investigators reported an approximate 26% reduction in total fat mass compared with placebo. Additional MRI-based analyses also demonstrated reductions in intramuscular fat accumulation, indicating improvements in overall body composition.

Researchers also noted that some loss of lean body mass occurs during significant weight reduction, regardless of treatment strategy. However, current evidence suggests that fat loss represents the largest proportion of weight reduction achieved with tirzepatide. Further long-term studies are needed to fully evaluate its effects on skeletal muscle preservation.

Why Does Tirzepatide Reduce Appetite?

One of tirzepatide’s most important therapeutic mechanisms is its ability to regulate appetite. By simultaneously activating GLP-1 and GIP receptors, the medication influences brain pathways responsible for hunger, satiety, and food reward.

Clinical studies demonstrated that after approximately 28 weeks of treatment, participants consumed substantially fewer calories during standardized meal tests. Average daily energy intake decreased by more than 300 kcal compared with placebo.

Participants also consistently reported:

• reduced feelings of hunger;
• earlier onset of fullness during meals;
• greater satiety after eating;
• fewer food cravings and less frequent snacking.

These appetite-regulating effects are considered one of the primary reasons behind the remarkable weight-loss outcomes observed throughout both the SURMOUNT and SURPASS clinical programs. Nevertheless, researchers emphasize that additional long-term studies are required to better understand how tirzepatide influences eating behavior over many years.

Effects of Tirzepatide on Blood Glucose and HbA1c

While tirzepatide has gained worldwide attention because of its weight-loss potential, its original therapeutic purpose was to improve glycemic control in adults with type 2 diabetes.

The primary endpoint in most SURPASS studies was the reduction of glycated hemoglobin (HbA1c), a laboratory marker reflecting average blood glucose levels over the previous two to three months.

Across multiple randomized clinical trials, tirzepatide consistently produced substantial improvements in glycemic control.

Depending on dosage, HbA1c decreased by approximately 20.4–28.2 mmol/mol after 40–52 weeks of treatment. Some Japanese studies reported even greater improvements among specific patient populations.

In addition to lowering HbA1c, tirzepatide demonstrated significant benefits in several important metabolic parameters, including:

• lower fasting blood glucose;
• improved insulin sensitivity;
• enhanced endogenous insulin secretion;
• better postprandial glucose control.

Large network meta-analyses have ranked tirzepatide among the most effective currently available medications for improving glycemic control in patients with type 2 diabetes.

How Does Tirzepatide Affect Cholesterol Levels?

Beyond improving body weight and blood glucose regulation, researchers have also investigated tirzepatide’s effects on lipid metabolism.

Across several clinical trials, treatment with tirzepatide was associated with:

• reduced total cholesterol;
• lower LDL (“bad”) cholesterol;
• decreased triglyceride concentrations;
• increased HDL (“good”) cholesterol.

Researchers also observed reductions in liver fat content among patients with metabolic dysfunction-associated fatty liver disease. Although much of this improvement is likely related to substantial weight loss, a direct metabolic effect of tirzepatide on lipid regulation cannot yet be excluded.

Key Benefits of Tirzepatide

• Clinically proven weight loss of up to 20.9%.
• Powerful improvements in HbA1c and overall glycemic control.
• Reduced appetite and lower daily calorie intake.
• Improved cholesterol and triglyceride levels.
• Potential reduction of liver fat accumulation.
• Convenient once-weekly dosing.
• Dual GLP-1/GIP receptor activation providing broader metabolic benefits than conventional GLP-1 therapies.

How Does Tirzepatide Affect Body Composition?

Successful weight management involves more than simply reducing body weight. From a clinical perspective, preserving lean muscle mass while reducing body fat is considered the ideal outcome.

Evidence from several clinical trials suggests that tirzepatide promotes weight loss primarily through reductions in adipose tissue rather than indiscriminate loss of total body mass.

In the SURPASS-1 trial, investigators reported an approximate 26% reduction in total fat mass compared with placebo. Additional MRI-based analyses also demonstrated reductions in intramuscular fat accumulation, indicating improvements in overall body composition.

Researchers also noted that some loss of lean body mass occurs during significant weight reduction, regardless of treatment strategy. However, current evidence suggests that fat loss represents the largest proportion of weight reduction achieved with tirzepatide. Further long-term studies are needed to fully evaluate its effects on skeletal muscle preservation.

Why Does Tirzepatide Reduce Appetite?

One of tirzepatide’s most important therapeutic mechanisms is its ability to regulate appetite. By simultaneously activating GLP-1 and GIP receptors, the medication influences brain pathways responsible for hunger, satiety, and food reward.

Clinical studies demonstrated that after approximately 28 weeks of treatment, participants consumed substantially fewer calories during standardized meal tests. Average daily energy intake decreased by more than 300 kcal compared with placebo.

Participants also consistently reported:

• reduced feelings of hunger;
• earlier onset of fullness during meals;
• greater satiety after eating;
• fewer food cravings and less frequent snacking.

These appetite-regulating effects are considered one of the primary reasons behind the remarkable weight-loss outcomes observed throughout both the SURMOUNT and SURPASS clinical programs. Nevertheless, researchers emphasize that additional long-term studies are required to better understand how tirzepatide influences eating behavior over many years.

Effects of Tirzepatide on Blood Glucose and HbA1c

While tirzepatide has gained worldwide attention because of its weight-loss potential, its original therapeutic purpose was to improve glycemic control in adults with type 2 diabetes.

The primary endpoint in most SURPASS studies was the reduction of glycated hemoglobin (HbA1c), a laboratory marker reflecting average blood glucose levels over the previous two to three months.

Across multiple randomized clinical trials, tirzepatide consistently produced substantial improvements in glycemic control.

Depending on dosage, HbA1c decreased by approximately 20.4–28.2 mmol/mol after 40–52 weeks of treatment. Some Japanese studies reported even greater improvements among specific patient populations.

In addition to lowering HbA1c, tirzepatide demonstrated significant benefits in several important metabolic parameters, including:

• lower fasting blood glucose;
• improved insulin sensitivity;
• enhanced endogenous insulin secretion;
• better postprandial glucose control.

Large network meta-analyses have ranked tirzepatide among the most effective currently available medications for improving glycemic control in patients with type 2 diabetes.

How Does Tirzepatide Affect Cholesterol Levels?

Beyond improving body weight and blood glucose regulation, researchers have also investigated tirzepatide’s effects on lipid metabolism.

Across several clinical trials, treatment with tirzepatide was associated with:

• reduced total cholesterol;
• lower LDL (“bad”) cholesterol;
• decreased triglyceride concentrations;
• increased HDL (“good”) cholesterol.

Researchers also observed reductions in liver fat content among patients with metabolic dysfunction-associated fatty liver disease. Although much of this improvement is likely related to substantial weight loss, a direct metabolic effect of tirzepatide on lipid regulation cannot yet be excluded.

Key Benefits of Tirzepatide

• Clinically proven weight loss of up to 20.9%.
• Powerful improvements in HbA1c and overall glycemic control.
• Reduced appetite and lower daily calorie intake.
• Improved cholesterol and triglyceride levels.
• Potential reduction of liver fat accumulation.
• Convenient once-weekly dosing.
• Dual GLP-1/GIP receptor activation providing broader metabolic benefits than conventional GLP-1 therapies.